India Pharma & Healthcare Stocks
Track 15 pharmaceutical and healthcare companies with historical returns, performance rankings, and investment analysis.
What's Driving Pharma Stock Returns?
Updated: May 2026India is the "pharmacy of the world"—the largest exporter of generic drugs, supplying 40% of US generic demand and 25% of global medicines. The sector benefits from both export growth and rising domestic healthcare spending.
Current performance: Pharma companies average +17.1% (1Y), while Hospital chains return +22.0%.
Key themes: US FDA approvals (generic launches drive revenue spikes), API manufacturing (China+1 beneficiary), specialty drugs shift, and domestic demand from rising health insurance coverage.
Of the 15 healthcare stocks tracked, 13 delivered positive returns over the past year. The top performer, LAURUSLABS, returned +70.0%, while MANKIND was the weakest at -16.8%. The median return was +14.8%.
Top 5 by 1-Year Return
Pharma Stocks Monthly Returns (Jun'25 – May'26)
Compare month-by-month performance. Green = gain, red = loss. Click any ticker for detailed analysis.
| Stock | Jun'25 | Jul'25 | Aug'25 | Sep'25 | Oct'25 | Nov'25 | Dec'25 | Jan'26 | Feb'26 | Mar'26 | Apr'26 | May'26 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LAURUSLABS | +19% | +21% | -2% | -2% | +13% | +8% | +7% | -13% | +11% | -8% | +5% | — | +71.2% |
| GLENMARK | +20% | +22% | -10% | +2% | -3% | +3% | +5% | -1% | +6% | -0% | -2% | — | +43.9% |
| TORNTPHARM | +8% | +10% | -5% | +1% | -1% | +5% | +3% | +3% | +10% | +1% | — | — | +39.5% |
| LUPIN | -1% | +0% | -2% | +1% | +3% | +6% | +1% | +2% | +7% | +1% | — | — | +19.0% |
| BIOCON | +6% | +10% | -11% | -2% | +9% | +7% | -1% | -7% | +6% | -2% | — | — | +14.3% |
| AUROPHARMA | -1% | +0% | -9% | +5% | +5% | +8% | -4% | +2% | +1% | +6% | — | — | +13.4% |
| FORTIS | +12% | +8% | +6% | +6% | +5% | -10% | -4% | -4% | +11% | -16% | -1% | — | +11.8% |
| APOLLOHOSP | +5% | +4% | +2% | -3% | +4% | -5% | -4% | -1% | +13% | -3% | — | — | +10.0% |
| SUNPHARMA | -0% | +2% | -7% | -0% | +6% | +8% | -6% | -7% | +10% | +4% | — | — | +8.5% |
| ALKEM | -3% | +2% | +6% | +2% | +2% | +3% | -3% | +3% | +0% | -6% | -1% | — | +4.1% |
| DRREDDY | +3% | -0% | -1% | -3% | -2% | +5% | +1% | -4% | +6% | +0% | — | — | +4.0% |
| ZYDUSLIFE | +6% | -1% | +1% | +0% | -1% | -3% | -3% | -3% | +4% | -2% | — | — | -1.5% |
| DIVISLAB | +3% | -3% | -7% | -7% | +18% | -4% | -1% | -5% | +6% | -5% | — | — | -7.8% |
| CIPLA | +4% | +3% | +2% | -5% | -0% | +2% | -1% | -12% | +2% | -2% | — | — | -9.3% |
| MANKIND | -6% | +11% | -4% | -1% | -2% | -6% | -2% | -3% | +6% | -11% | -0% | — | -19.0% |
Industry Breakdown
All Healthcare Stocks
Sorted by market capitalization. The three largest — SUNPHARMA, DIVISLAB, TORNTPHARM — represent 43% of the sector.
| Stock | Market Cap | 1Y Return | 5Y Return | 10Y Return |
|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries | ₹4.3L Cr | +13.1% | +203.5% | +140.4% |
| DIVISLAB Divi's Laboratories Limited | ₹1.6L Cr | +9.3% | +68.1% | +464.6% |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹1.5L Cr | +44.1% | +265.0% | +586.3% |
| APOLLOHOSP Apollo Hospitals Enterprise | ₹1.1L Cr | +21.8% | +174.2% | +435.1% |
| DRREDDY Dr. Reddy's Laboratories | ₹1.1L Cr | +14.8% | +37.6% | +122.3% |
| CIPLA Cipla Limited | ₹1.1L Cr | -8.9% | +62.1% | +114.2% |
| LUPIN Lupin Limited | ₹1.1L Cr | +14.7% | +124.6% | +32.8% |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹91K Cr | +1.7% | +100.8% | +197.8% |
| MANKIND Mankind Pharma Limited | ₹83K Cr | -16.8% | N/A | N/A |
| AUROPHARMA Aurobindo Pharma Limited | ₹75K Cr | +16.8% | +39.8% | +56.1% |
| ALKEM Alkem Laboratories Limited | ₹63K Cr | +5.5% | +100.3% | +332.1% |
| BIOCON Biocon Limited | ₹62K Cr | +15.1% | -4.3% | +353.5% |
| FORTIS Fortis Healthcare Limited | ₹60K Cr | +22.3% | +399.2% | +363.6% |
| GLENMARK Glenmark Pharmaceuticals Limited | ₹59K Cr | +43.5% | +350.5% | +177.0% |
| LAURUSLABS Laurus Labs Limited | ₹56K Cr | +70.0% | +196.5% | N/A |
About India Pharma Stocks
India's pharmaceutical industry is the world's third-largest by volume and a leading exporter of generic drugs. Indian companies manufacture over 60,000 different drug formulations and export to 200+ countries.
Key Investment Themes
- US generics market: India supplies 40% of US generic drug demand. FDA approvals drive revenue spikes.
- API manufacturing: India is the "China+1" beneficiary for Active Pharmaceutical Ingredients sourcing.
- Specialty & complex generics: Higher margins in biosimilars, injectables, and complex molecules.
- Domestic demand: Rising health insurance coverage (Ayushman Bharat) driving volume growth.
- R&D investment: Top players investing in novel drug development beyond generics.
Risks to Watch
- FDA inspections: Warning letters can halt US exports and tank stock prices.
- Pricing pressure: US drug price reforms and consolidation of PBMs squeeze margins.
- Currency volatility: USD/INR impacts export realizations.